Anzeige
Mehr »
Login
Montag, 13.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Die 1 Billionen Dollar Mine: Power Nickels Weg zur globalen Dominanz!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
383 Leser
Artikel bewerten:
(2)

Engage Venture Partners Launches as New Medtech Venture Capital Firm, Announces Initial Investment

Finanznachrichten News

Founded by a team with proven track records in healthcare, medical devices, investing, and startup operations, the firm's innovative investment approach leverages industry access and provides a flexible, investor-friendly structure.

MINNEAPOLIS, MN / ACCESSWIRE / July 14, 2022 / Engage Venture Partners, a new venture capital (VC) firm focused on medical technology companies, announces its launch and inaugural company investment. Backed by deep technical expertise, extensive due diligence capabilities, and specialized industry knowledge, Engage was established to address the need for a more accessible, lower-friction funding community for seed- and early-growth stage medtech companies and their investors.

Engage Venture Partners, Thursday, July 14, 2022, Press release picture

Engage also announced its first investment with Minnesota-based medical device manufacturer Melodi Health. Melodi offers surgical solutions to women undergoing breast surgery by developing a novel absorbable scaffold intended to support soft tissue and improve patient outcomes.

"The Engage team pulled together a group of mature angel investors that aligned with our timeline and investment stage and who were uniquely qualified to invest in our platform, including surgeons and seasoned medtech investors," says Sarah Worrell, CEO of Melodi Health.

Engage organizes Special Purpose Vehicles (SPVs), each of which is a legal entity created for the specific purpose of investing in a single startup. This next-generation investment model offers investors lower management fees, individual flexibility and control, and lower investment minimums that allow for broader participation and access.

"The Engage SPV was an efficient, well-organized way for Melodi to raise a meaningful amount of capital that significantly funds our pre-commercial development activities aimed at impacting outcomes for women with breast cancer undergoing post-mastectomy reconstruction on their journey to recovery," notes Worrell.

Located in Minnesota's Medical Alley, one of the top health tech clusters in the world with more than 1,000 healthcare technology companies, Engage offers investors access to extensively vetted medtech startups and an advisory network with deep domain expertise in selected subsectors, including medical device, biotech, pharma, and digital health.

"Minnesota is a global center of medtech innovation," says Steve Sigmond, founder and managing director at Engage. "Our team's deal flow, combined with our proprietary research and due diligence capabilities, allow us to offer value to investors on day one."

The Engage Venture Partners team consists of four founders, two of whom serve as managing directors. With more than 25 years of experience in investing, advising, and running early stage companies, Sigmond was most recently founder, CFO, and vice president of marketing for Carrot Health, a Minneapolis-based healthcare analytics SaaS company that was acquired in 2021. Kelly Prchal, founder and managing director, is an active angel investor with nearly 20 years of experience across the healthcare continuum and co-founder of AlliedVirtualCare, a technology health and wellbeing company focused on age-related hearing loss and related conditions.

Joining Sigmond and Prchal as Engage founders are Morgan Evans and Ryan Spanheimer. Evans is a medtech founder and executive who is also co-founder and CEO of Agitated Solutions, Inc., a medical device company; co-founder of Moonshot Medical, a medical device incubator; and founder and executive director of Highland Circle Innovations, a medtech services firm.

Evans notes: "We have institutional-quality deal flow and the highest rigor in due diligence, but at the end of the day we are most passionate about directing resources to people who are doing amazing work."

A practicing patent attorney with a specialization in medical technology, Spanheimer has worked extensively with medical device companies in a variety of fields. He offers a detailed understanding of technology development and market commercialization and works regularly with both early stage and mature medtech businesses to spot technical disruption and growth opportunities in relevant target markets.

To learn more about Engage and investment opportunities, email investors@engagevp.com.

About Engage Venture Partners
Minneapolis-based and woman-owned, Engage Venture Partners is a research-driven venture capital firm focused on early-stage medtech investments. With extensive healthcare and medical device industry knowledge, and decades of experience in investing and startup operations, Engage delivers a flexible and investor-friendly structure utilizing Special Purpose Vehicles (SPVs). Accredited investors are invited to join the Engage Investor Network, which requires neither a fee to join nor minimum commitment. Email investors@engagevp.com to learn more.

ENGAGE'S SERVICES, ENGAGE ADMINISTERED INVESTMENT OPPORTUNITIES, AND ENGAGE MATERIALS ARE PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DO NOT CONSTITUTE INVESTMENT, LEGAL, OR TAX ADVICE. NOTHING PROVIDED BY ENGAGE CONSTITUTES A SOLICITATION, RECOMMENDATION, ENDORSEMENT, OR OFFER BY ANY ENGAGE PARTY, THE TARGET, OR ANY THIRD-PARTY SERVICE PROVIDER TO BUY OR SELL ANY SECURITIES OR OTHER FINANCIAL INSTRUMENTS IN MINNESOTA OR IN IN ANY OTHER JURISDICTION IN WHICH SUCH SOLICITATION OR OFFER WOULD BE UNLAWFUL UNDER THE SECURITIES LAWS OF SUCH JURISDICTION. THERE ARE RISKS ASSOCIATED WITH INVESTING IN SECURITIES, INCLUDING WITHOUT LIMITATION, THE RISK OF COMPLETELY LOSING ANY AND ALL INVESTED AMOUNTS.

# # #

Media Contact:

Liz Goar
NPC Creative Services
liz@npccs.com

SOURCE: Engage Venture Partners



View source version on accesswire.com:
https://www.accesswire.com/708411/Engage-Venture-Partners-Launches-as-New-Medtech-Venture-Capital-Firm-Announces-Initial-Investment

© 2022 ACCESSWIRE
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.